MEN for multiple endocrin neoplasms: When evokate MEN? Update 2022

• Published in: La revue de medecine interne Vol. 44; no. 1; p. 12
• Main Authors: Duval, M, Haissaguerre, M
• Format: Journal Article
• Language: English; French
• Published: France 01-01-2023
• Subjects: Adrenal Gland Neoplasms - diagnosis; Genetic Testing; Humans; Multiple Endocrine Neoplasia - diagnosis; Multiple Endocrine Neoplasia - genetics; Mutation; Pheochromocytoma - diagnosis; Syndrome; Thyroid Neoplasms; neuroendocrines; Adénomes hypophysaires; Hyperparathyroïdie; Pituitary adenomas; Multiple endocrine neoplasia (MEN); Carcinome médullaire thyroïdien; Hyperparathyroidism; Medullary thyroid carcinoma; Néoplasie endocrinienne multiple (NEM); Neuroendocrine tumors; Tumeurs
• ISSN: 1768-3122
• DOI: 10.1016/j.revmed.2022.10.002

Multiple endocrine neoplasia (MEN) are genetic predisposition syndromes to endocrine tumors including MEN1, MEN2 and exceptionally MEN4. MEN are transmitted in an autosomal dominant fashion with a high penetrance. Classically, there is no genotype/phenotype correlation for NEM1 whereas this is the case for NEM2. Patients with NEM1, linked to an inactivating mutation of the menin gene, may present with: primary hyperparathyroidism, pituitary adenoma, duodeno-pancreatic neuroendocrine tumors (NETs), bronchial tumors with an increased risk of thymoma, adrenal cortical tumors, an increased risk of breast cancer and characteristic skin involvement such as collagenomas, lentiginomas and an increased risk of skin cancer. These patients require at least annual follow-up. Screening of children is proposed from the age of 5 years. Patients with NEM2, linked to an activating mutation of the RET proto-oncogene, all present with medullary thyroid carcinoma (MTC) at a variable age depending on the genotype. Some patients present a pheochromocytoma (50 %) and hyperparathyroidism (20 %). Pediatric forms with aggressive CMT, ganglioneuromatosis and marfanoid syndrome exist (rare NEM2B). Some mutations are associated with a risk of aggressive CMT, justifying prophylactic thyroidectomy before 6 months of age. The age of genetic testing depends on the mutation subtype in the NEM2 parent. NEM4, related to a mutation in the CDKN1B gene, are rare, with a less well-known pathogenesis and their follow-up is not well codified.